Acute myelocytic leukemia in adults Academic Article Article uri icon


MeSH Major

  • Cardiovascular Diseases
  • Genetic Variation
  • Indians, North American
  • Mannose-Binding Lectin


  • The proposed reasons why acute myelocytic leukemia (AML) is less responsive to chemotherapy than lymphoblastic leukemia are examined. It is concluded that neither difference in age incidence nor difference in pathogenesis provides adequate explanations and that the major reasons why chemotherapy is less successful in AML are because: 1. None of the available cytotoxic drugs is sufficiently selective in killing leukemic myeloblasts and thus remission induction is very hazardous, and 2. There are relatively few drugs available which are dependably lethal to leukemic myeloblasts, thereby hindering effective remission consolidation. Despite these obstacles, several regimens employing combinations of drugs have recently been reported which give remission rates of 50% or better and significant prolongation of survival. The current status of one of these regimens—the “L‐6” protocol —is reviewed and discussed in relation to anticipated future developments. Copyright © 1972 American Cancer Society

publication date

  • January 1972



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/1097-0142(197212)30:6<1572::AID-CNCR2820300624>3.0.CO;2-M

PubMed ID

  • 4509106

Additional Document Info

start page

  • 1572

end page

  • 82


  • 30


  • 6